Home page > WHAT TO PUT HERE ???

clinical trials


Please find all related articles below.



[European Commission report] Personalised Medicine


The European Commission has recently published a Staff Working Document (SWD) exploring the potential of Personalised Medicine, reporting on recent developments in the EU legislation, as well as looking at the factors affecting the uptake of personalised medicine in healthcare systems. Personalised Medicine is now more close to be effective to patients, which means that treatments can be designed taking into account a specific patient group and hence able to tackle the problem with the (...)
Also about: Access to Medicines , Pharmaceuticals and Medicines , Health Rights and Patients , Research , Patient safety , health literacy , Health Inequalities , medical devices , Innovation , pharmacovigilance , health system
18/11/2013

Health priorities of the Lithuanian Presidency of the EU Council


The Lithuanian Presidency, which will be the last full EU Council presidency before the European elections of 2014, will focus its efforts in attaining a credible, growing and open Europe, building on the cooperation with its Trio partners. Lithuania will focus its efforts in the following health issues. The Lithuanian Priorities for health Advancing legislative initiatives Revision of the Tobacco Products Directive (high priority) Lithuania has confirmed its commitment to continue (...)
Also about: Air Quality and Air Pollution , Chronic Diseases , Transparency , food safety , WHO , Cross Border Healthcare Directive , medical devices , Tobacco Products Directive (TPD)
08/07/2013

Public consultation on Declaration of Helsinki on medical research involving human subjects


A two-month public consultation (15 April to 15 June 2013) on the World Medical Association’s Declaration of Helsinki on medical research involving human subjects has been launched by the World Medical Association. A revised version of the Declaration is available on the WMA website. This consultation is of particular interest in the context of the ongoing revision of the Clinical Trials legislation. Please click here for detailed information on the consultation process The (...)
Also about: Health professionals , Research , Health Inequalities , medical devices , vulnerable groups , women health
25/04/2013

Clinical trials: Exploring the limits of transparency


Glenis Willmott MEP (S&D, UK) took the initiative to bring together experts to discuss the extent to which more transparency could be workable in non-commercial clinical trials. The debate, which took place in the European Parliament on 10 April, served to present the key arguments for and against increased transparency in the context of administrative and data reporting requirements for academic researchers and patient safety. EPHA’s Position on Clinical Trials urges political (...)
Also about: Pharmaceuticals and Medicines , Health Rights and Patients , Health professionals , Research , Healthcare services , Transparency , Health Inequalities , public health , patient rights , pharmacovigilance , health system
25/04/2013

[Special Summary] EU General Data Protection Regulation and Health Research


On 17 December 2012, the European Parliament’s Committee on Civil Liberties, Justice and Home Affairs (LIBE) released its draft report on the European Commission’s proposal for a regulation on the processing and free movement of personal data. The proposal and the amendments offered in the draft report have implications for a number of elements of health, inlcuding health research. This article takes a closer look at the potential effects of the new legislation for research (...)
Also about: Research , health system , data protection
22/02/2013

Ireland’s Presidency Health Priorities presented


Ireland, in collaboration with its TRIO partners - Lithuania and Greece - has made a commitment to use its resources to prioritise solid progress on a number of key legislative dossiers in health and calls on member states to work together, sharing ideas, information and best practice. The Irish Presidency Programme, whose cornerstone is progressing the legislative agenda, contains a series of health priorities: on 23 January 2013 the Irish Minister of Health, James Reilly, presented them (...)
Also about: tobacco and smoking , Cross Border Healthcare Directive , eHealth , medical devices , public health programme
17/02/2013

[Revised EPHA position] Clinical Trials


EPHA has revised its position on clinical trials following the European Commission’s release of a legislative proposal for a regulation over the summer. While the key elements remain the same, the updated version emphasises the need for clinical trials to go ahead so that different population groups can benefit from life-saving treatments, while underlining that patient safety must remain at the centre of the process, and not compromised by less rigid assessment procedures. The (...)
Also about: Ageing and Older People , Access to Medicines , Pharmaceuticals and Medicines , Health professionals , Research , Health Inequalities , public health , Innovation , health system , health economics , women health
29/11/2012

Clinical Trials: European Commission revamps the EU rules


The European Commission has published its draft proposal to revise the Clinical Trial Directive. According to the European Commission, the main aim of the revised proposal is to simplify the rules for conducting clinical trials in Europe, while maintaining the highest standards of patient safety. Once adopted, the proposed Regulation will replace the 2001 ’Clinical Trials Directive’. The objective is to ensure that Clinical Trials rules are identical throughout the EU. The (...)
Also about: Pharmaceuticals and Medicines , Research , Patient safety , patient rights , Innovation
18/07/2012

The European Medicines Agency launches website on new European database of suspected adverse drug reaction


The European Medicines Agency (EMA) launched last May 31st the new European database of suspected adverse drug reaction reports website. The launch of this website is a positive first step in the implementation of the EudraVigilance access policy. The information carried on the site relates to approximately 650 medicines and active substances authorised through the centralised procedure. Within a year the EMA aims to additionally publish suspected side-effect reports for common drug (...)
Also about: Pharmaceuticals and Medicines , Drugs and Substance Dependance , health literacy , patient rights , antibiotic , drug resistance , counterfeit , pharmacovigilance , EMA
28/06/2012

’’Recognise contribution of intensive care’’, urges MEP Buşoi at European Parliament event


On 15 May 2012, EPHA co-organised an event in collaboration with our member the European Society of Intensive Care Medicine (ESICM) at the European Parliament. Cristian Buşoi MEP (ALDE, Romania) hosted and moderated a policy debate on the contribution of ’’intensivists’’ to better patient outcomes and health systems, tied to the launch of a two-day exhibition to promote the ESCIM’s LIFE-PRIORITY campaign. The overall aim of the policy debate, entitled (...)
Also about: Health professionals , Research , Patient safety , public health , technology , medical devices , health threats , Directive 36 , health economics , Intensive Care Medicine
25/05/2012